ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Charles L. Bennett, MD, PhD, MPP, and James O. Armitage, MD, on Biosimilars in Oncology

Charles L. Bennett, MD, PhD, MPP of the University of South Carolina College of Pharmacy, and James O. Armitage, MD, of the University of Nebraska Medical Center, discuss the emerging and future benefits of biosimilars.

Sarcoma

Patrick Schöffski, MD

Patrick Schöffski, MD, on Eribulin for Soft-Tissue Sarcomas

Patrick Schöffski, MD, of the University Hospital Leuven, discusses a phase III study in which he and his colleagues found, for the first time in soft-tissue sarcomas, a significant overall survival benefit of a single agent compared to a standard treatment (Abstract LBA10502).

Breast Cancer

Maura N. Dickler, MD and Clifford A. Hudis, MD

Maura N. Dickler, MD, and Clifford A. Hudis, MD, on Results From the CALGB Alliance Trial on Hormone Receptor–Positive Advanced Breast Cancer

Clifford A. Hudis, MD, and Maura N. Dickler, MD, of Memorial Sloan Kettering Cancer Center, discuss adding bevacizumab to letrozole as a first-line endocrine therapy for treatment of hormone receptor–positive advanced breast cancer (Abstract 501).

Colorectal Cancer

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD, on HERACLES and Other Colorectal Cancer Findings

Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, and Axel Grothey, MD, of the Mayo Clinic, discuss the Italian-led study on trastuzumab and lapatinib in HER2-amplified metastatic colorectal as well as other colorectal cancer findings discussed at ASCO (Abstract 3508).

Skin Cancer

Andrew James Martin, PhD

Andrew James Martin, PhD, on Oral Nicotinamide for Nonmelanoma Skin Cancer

Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, discusses a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).

Oct

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Charles L. Bennett, MD, PhD, MPP, and James O. Armitage, MD, on Biosimilars in Oncology

Patrick Schöffski, MD, on Eribulin for Soft-Tissue Sarcomas

Maura N. Dickler, MD, and Clifford A. Hudis, MD, on Results From the CALGB Alliance Trial on Hormone Receptor–Positive Advanced Breast Cancer

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD, on HERACLES and Other Colorectal Cancer Findings

Andrew James Martin, PhD, on Oral Nicotinamide for Nonmelanoma Skin Cancer

HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy

GLP-1 Receptor Agonist Use Linked to Lower Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease

Pediatric Bone Sarcoma Gets First NCCN Guidelines

2026 Albany Prize Awardees Announced

ACS Study Quantifies Financial Burden of Cancer in Older Patients